Search Results - "Dieci, M.V."

Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials by Dieci, M.V., Mathieu, M.C., Guarneri, V., Conte, P., Delaloge, S., Andre, F., Goubar, A.

“…Tumor-infiltrating lymphocytes (TILs) are emerging as strong prognostic factor for early breast cancer patients, especially in the triple-negative subtype…”
Get full text

Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study by Dieci, M.V., Criscitiello, C., Goubar, A., Viale, G., Conte, P., Guarneri, V., Ficarra, G., Mathieu, M.C., Delaloge, S., Curigliano, G., Andre, F.

“…There is a need to develop surrogates for treatment efficacy in the neoadjuvant setting to speed-up drug development and stratify patients according to…”
Get full text

Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy by Luen, S.J., Salgado, R., Dieci, M.V., Vingiani, A., Curigliano, G., Gould, R.E., Castaneda, C., D’Alfonso, T., Sanchez, J., Cheng, E., Andreopoulou, E., Castillo, M., Adams, S., Demaria, S., Symmans, W.F., Michiels, S., Loi, S.

“…For primary triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NAC), higher pretreatment tumor-infiltrating lymphocytes (TILs)…”
Get full text

Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study by Dieci, M.V., Criscitiello, C., Goubar, A., Viale, G., Conte, P., Guarneri, V., Ficarra, G., Mathieu, M.C., Delaloge, S., Curigliano, G., Andre, F.

Get full text

Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-Institution analysis by Dieci, M.V., Barbieri, E., Piacentini, F., Ficarra, G., Bettelli, S., Dominici, M., Conte, P.F., Guarneri, V.

“…Tumor phenotype may change during breast cancer progression. This study evaluates the prognostic impact of receptor discordance between paired primaries and…”
Get full text

Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients by Guarneri, V., Dieci, M.V., Barbieri, E., Piacentini, F., Omarini, C., Ficarra, G., Bettelli, S., Conte, P.F.

“…Emerging literature data are showing that a change in human epidermal growth factor receptor (HER2) status adversely affects breast cancer patient's prognosis…”
Get full text

Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer by Guarneri, V, Barbieri, E, Dieci, M.V, Piacentini, F, Conte, P

“…SUMMARY Since the introduction of anti-Her2 agents, the prognosis of HER2 positive breast cancer patients significantly improved. In the adjuvant setting, the…”
Get full text

Fat grafting for breast cancer patients: from basic science to clinical studies by Gennari, R, Griguolo, G, Dieci, M.V, Guarneri, V, Sibilio, A, Conte, P

“…Abstract Fat grafting in the surgical treatment of breast cancer has become popular in a short period of time because of the rising expectations of good…”
Get full text

117O Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: A meta-analysis of randomised trials by Guarneri, V., Griguolo, G., Miglietta, F., Conte, P.F., Dieci, M.V., Girardi, F.

Get full text

Temporal evolution of breast cancer brain metastases treatments and outcomes by Bottosso, M., Griguolo, G., Miglietta, F., Guarascio, M.C., Cattelan, A.C., Zurlo, C., Aldegheri, V., Marino, M., Zanghì, F., Giorgi, C.A., Vernaci, G., Girardi, F., Dieci, M.V., Guarneri, V.

Get full text

Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial by Dieci, M.V., Prat, A., Tagliafico, E., Paré, L., Ficarra, G., Bisagni, G., Piacentini, F., Generali, D.G., Conte, P., Guarneri, V.

“…The aim of this work was to evaluate the impact of (and relative contribution of) tumor-related and immune-related diversity of HER2-positive disease on the…”
Get full text

The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes by Bonanno, L., Pavan, A., Dieci, M.V., Di Liso, E., Schiavon, M., Comacchio, G., Attili, I., Pasello, G., Calabrese, F., Rea, F., Favaretto, A., Rugge, M., Guarneri, V., Fassan, M., Conte, P.F.

“…The prognosis of small-cell lung cancer (SCLC) is dismal and new effective therapies are needed. Immunotherapy looks promising, but no molecular predictive…”
Get full text

De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study by Guarneri, V., Dieci, M.V., Bisagni, G., Frassoldati, A., Bianchi, G.V., De Salvo, G.L., Orvieto, E., Urso, L., Pascual, T., Paré, L., Galván, P., Ambroggi, M., Giorgi, C.A., Moretti, G., Griguolo, G., Vicini, R., Prat, A., Conte, P.F.

“…In human epidermal growth factor receptor 2 (HER2+) breast cancers, neoadjuvant trials of chemotherapy plus anti-HER2 treatment consistently showed lower…”
Get full text

240P Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases by Bottosso, M., Griguolo, G., Sinoquet, L., Guarascio, M.C., Aldegheri, V., Miglietta, F., Barbieri, C., Girardi, F., Jacot, W., Guarneri, V., Darlix, A., Dieci, M.V.

Get full text

Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival by Miglietta, F., Bottosso, M., Griguolo, G., Dieci, M.V., Guarneri, V.

“…In the last years we have witnessed tremendous advancements in the treatment landscape of metastatic breast cancer (MBC), leading to a progressive prolongation…”
Get full text

26P Evaluation of tumor-infiltrating lymphocytes on matched baseline and residual disease samples of triple-negative breast cancer patients treated with anthracycline-taxane based neoadjuvant chemotherapy with or without carboplatin by Miglietta, F., Zarrilli, G., Massa, D., Griguolo, G., Fassan, M., Bottosso, M., Giorgi, C.A., Giarratano, T., Vernaci, G., Cesarotto, M., Guarascio, M.C., Guarneri, V., Dieci, M.V.

Get full text

479P Radiomics to predict HER2 status in breast cancer brain metastases by Griguolo, G., Gabelloni, M., Fusco, R., Jacot, W., Guarascio, M.C., Francischello, R., Bauchet, L., Granata, V., Faggioni, L., Bottosso, M., Rigau, V., Dieci, M.V., Neri, E., Darlix, A., Guarneri, V.

Get full text

276P Development and external validation of an artificial intelligence (AI)-based machine learning model (ML) for predicting pathological complete response (pCR) in hormone-receptor (HoR)-positive/HER2-negative early breast cancer (EBC) undergoing neoadjuvant chemotherapy (NCT) by Mastrantoni, L., Garufi, G., Di Monte, E., Arcuri, G., Frescura, V., Maliziola, N., Rotondi, A., Giordano, G., Carbognin, L., Fabi, A., Paris, I., Franceschini, G., Orlandi, A., Palazzo, A., Puglisi, F., Dieci, M.V., Milella, M., Scambia, G., Tortora, G., Bria, E.

Get full text

Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer by Dieci, M.V., Conte, P., Bisagni, G., Brandes, A.A., Frassoldati, A., Cavanna, L., Musolino, A., Giotta, F., Rimanti, A., Garrone, O., Bertone, E., Cagossi, K., Sarti, S., Ferro, A., Piacentini, F., Maiorana, A., Orvieto, E., Sanders, M., Miglietta, F., Balduzzi, S., D’Amico, R., Guarneri, V.

“…There is the need to identify new prognostic markers to refine risk stratification for HER2-positive early breast cancer patients. The aim of this study was to…”
Get full text

103P Rate of BRCA1/2 pathogenic variants according to family and personal history of cancer in a large cohort of triple-negative breast cancer (TNBC) patients (pts) younger than 60 years of age by Zovato, S., Griguolo, G., Agata, S., Tognazzo, S., Dieci, M.V., Matricardi, L., Crivellari, G., Miglietta, F., Alducci, E., Moserle, L., Conte, P.F., Montagna, M., Guarneri, V.

Get full text